Dewas, Madhya Pradesh, India, April 2025 – Dr. Vikas Patil has joined Navin Molecular, the CDMO division of Navin Fluorine, as Director, Group Leader – Process Development, R&D. In this strategic leadership role, Dr. Patil will spearhead innovative process development initiatives, contributing to Navin Molecular’s mission of delivering safe, scalable, and first-time-right solutions for complex small molecule targets.
Before joining Navin Molecular, Dr. Vikas Patil served at Aragen Life Sciences for nearly five years, where he held key roles including Associate Director and Principal Scientific Manager. During this time, he led scientific teams focused on advanced process development and scale-up strategies aligned with global pharmaceutical standards.
Earlier, Dr. Patil worked as Assistant General Manager at Optimus Drugs Pvt. Ltd., where he managed critical development projects and mentored cross-functional R&D teams. His role involved process optimization, regulatory compliance, and strategic planning to support commercial manufacturing.
Prior to that, he served as Manager at Aurobindo Pharma Research Centre, contributing significantly to generic API development and process validation. He also briefly held the position of Group Leader at Cipla, focusing on pilot plant technology transfer and regulatory support.
Dr. Patil began his research career at Jubilant Chemsys, where he advanced through multiple positions over nearly nine years, ultimately serving as Research Scientist-II. His early contributions to Torrent Research Centre and Aarti Drugs Ltd. further shaped his foundational expertise in R&D, synthesis, and process chemistry.
About Navin Molecular
Navin Molecular, a division of Navin Fluorine, is a technology-driven Contract Development and Manufacturing Organization (CDMO) that specializes in small molecule pharmaceutical solutions. With strong process development capabilities and a deep understanding of regulatory frameworks, Navin Molecular offers safe, scalable, and innovative solutions that support customers from early-stage development to commercial manufacturing. Their commitment to “first-time-right” piloting and cGMP production has positioned them as a trusted partner for the pharmaceutical industry.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
